• Aclacinomycin A: Precision DNA Damage & Apoptosis Workflows

  2026-05-30

  Aclacinomycin A (Aclarubicin) stands apart as a dual topoisomerase inhibitor and apoptosis inducer, enabling high-resolution interrogation of DNA damage and nucleolar stress responses. This guide demystifies experimental workflows, troubleshooting, and the latest nucleolar DNA damage insights using APExBIO’s validated reagent.

• Radicicol (A4067): Reliable Hsp90 Inhibitor for Assay Precis

  2026-05-29

  This scenario-driven article addresses critical laboratory challenges in cell viability, adipogenesis, and inflammation assays, illustrating how Radicicol (SKU A4067) offers reproducible, data-backed solutions. Leveraging its validated mechanism as an Hsp90 and PDK3 inhibitor, Radicicol supports robust experimental design and data interpretation for advanced biomedical research.

• Senolytic Activity of L. plantarum DS0037 ELNs: Mechanistic

  2026-05-29

  The referenced study identifies exosome-like nanovesicles (ELNs) from Lactobacillus plantarum DS0037 as potent, selective senolytic agents that target senescent cells and modulate key aging and inflammatory markers. These findings highlight the translational potential of microbial-derived ELNs for developing anti-aging interventions with improved specificity and mechanistic clarity.

• Doxorubicin (Adriamycin): Mechanism, Evidence & Applications

  2026-05-28

  Doxorubicin (Adriamycin) is an anthracycline antibiotic used as a chemotherapeutic agent for solid tumors and hematologic malignancy research. It primarily inhibits DNA topoisomerase II, causing DNA damage and apoptosis in cancer cells. This article details its mechanism, benchmarks, and protocol integration for advanced cancer research.

• Targeting c-Myc with 10074-G5: Strategic Advances in Cancer

  2026-05-28

  This thought-leadership article examines the mechanistic and translational potential of 10074-G5, a small-molecule c-Myc inhibitor from APExBIO, for disrupting oncogenic transcriptional networks in cancer research. By integrating recent discoveries on the MYC/TERT/NFκB axis and drawing on protocol insights from leading translational workflows, we explore how 10074-G5 enables rigorous apoptosis and tumor regression studies while addressing real-world challenges of target validation and clinical translatability.

• Plk1-Mediated Regulation of p31comet in Mitotic Checkpoint D

  2026-05-27

  This study elucidates how Polo-like kinase 1 (Plk1) regulates the mitotic checkpoint by phosphorylating p31comet, thereby controlling the disassembly of mitotic checkpoint complexes (MCCs). The findings clarify a critical mechanism preventing futile MCC cycling, with implications for understanding cell division fidelity and potential translational research in checkpoint modulation.

• Phosbind Acrylamide: Precision Phosphate-Binding for SDS-PAG

  2026-05-27

  Phosbind Acrylamide enables high-fidelity protein phosphorylation analysis by facilitating antibody-free SDS-PAGE separation of phosphorylated proteins. This phosphate-binding reagent operates at physiological pH, supporting robust kinase signaling and metabolic research.

• Ibrexafungerp and Caspofungin Against Resistant Candida auri

  2026-05-26

  Wiederhold et al. provide robust evidence that ibrexafungerp, a first-in-class triterpenoid, and caspofungin, a lipopeptide antifungal drug, both demonstrate strong efficacy against fluconazole-resistant Candida auris in vitro and in vivo. Their findings illuminate the critical role of β-(1,3)-D-glucan biosynthesis inhibition for managing multidrug-resistant fungal infections.

• Systematic Analysis of AKT Inhibitors Reveals Functional Div

  2026-05-26

  This study systematically compares ATP-competitive and allosteric AKT inhibitors, revealing distinct pharmacological profiles and mechanisms of resistance. These findings inform the rational design of combination therapies and highlight the importance of inhibitor class in targeting oncogenic PI3K–AKT signaling.

• HyperPFU™ High-Fidelity DNA Polymerase: Technical PCR Guidan

  2026-05-25

  HyperPFU™ high-fidelity DNA polymerase enables accurate PCR amplification of long or GC-rich DNA fragments that are challenging for conventional enzymes. It should be chosen for workflows requiring blunt-ended, high-fidelity DNA but avoided in protocols depending on 3'-A overhangs or sticky-end generation.

• Cabozantinib (XL184, BMS-907351): Reliable Lab Solutions for

  2026-05-25

  This article addresses real laboratory challenges in cell viability, proliferation, and phosphoproteomics by demonstrating how Cabozantinib (XL184, BMS-907351) (SKU A2977) delivers reproducible, literature-backed results. Scenario-based Q&A blocks guide researchers through protocol optimization, data interpretation, and vendor selection, leveraging validated performance data to support robust cancer biology research.

• Syringin Natural Product: Advanced Workflows in Apoptosis Re

  2026-05-24

  Syringin, a natural product from APExBIO, is redefining apoptosis and drug resistance research through potent modulation of the EGFR/PI3K/Akt pathway. This guide details actionable protocols, comparative advantages, and troubleshooting tips to maximize experimental success in signaling pathway modulation and bioactive compound screening.

• SU 5402 in Precision Oncology: Mechanisms, Assay Design, and

  2026-05-23

  Explore SU 5402’s advanced role in cancer biology and cell signaling research. This in-depth article reveals unique mechanistic insights, protocol optimizations, and the latest translational findings for multiple myeloma and beyond.

• Neddylation Inhibition Alters Glutamine Metabolism via SPOP-

  2026-05-22

  This article discusses how targeted neddylation inhibition in cancer cells increases glutamine uptake by stabilizing the glutamine transporter ASCT2, mediated through the CRL3-SPOP E3 ligase pathway. The findings reveal a metabolic vulnerability in tumors and suggest combinatorial strategies for enhancing antitumor therapies.

• Caspofungin: Strategic Leverage in Translational Antifungal

  2026-05-22

  This thought-leadership article explores the mechanistic and translational value of Caspofungin, a lipopeptide antifungal drug, for researchers confronting the escalating threat of resistant Candida infections. Integrating molecular insight, comparative efficacy data, and strategic workflow guidance, it articulates actionable paths for innovation in fungal therapeutics.

15686 records 1/1046 page Next 12345 下5页 Last page